No results for ‘’
Panacea Biotec Ltd
₹397.65
(2.32%)
Wed, 16 Sept 2026, 11:07 am
Health Technology
Pharmaceuticals: Major
24.5KPanacea Biotec Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 41.13 | 19.02 | 17.68 | 0 | 19.26 | 7.95 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.18 | 0 | 0 | 0.84 | 0 | 0 | 0 |
| Price to book ratio | 14.15 | 5.09 | 3.22 | 0.64 | 2.10 | 1.72 | 0.57 | 1.22 | 1.13 | 1.89 | 1.32 | 2.77 | 5.30 | 3.46 | 3.37 | 0 | 1.04 | 0.79 | 0.88 | 3.23 |
| Price to sales ratio | 4.21 | 3.30 | 2.82 | 0.53 | 1.75 | 1.01 | 0.72 | 1.33 | 1.17 | 1.27 | 0.91 | 1.85 | 2.79 | 2.68 | 1.25 | 1.76 | 1.38 | 1.45 | 1.34 | 5.47 |
| Price to cash flow ratio | 14.85 | 17.25 | 38.79 | 0 | 54.85 | 28.14 | 2.95 | 0 | 0 | 52.42 | 34.22 | 29.65 | 191.82 | 30.54 | 0 | 100.62 | 0 | 0 | 58.76 | 0 |
| Enterprise value | 2515Cr | 2810Cr | 2615Cr | 1051Cr | 2235Cr | 1967Cr | 1367Cr | 1706Cr | 1625Cr | 1919Cr | 1650Cr | 1974Cr | 2549Cr | 1834Cr | 1320Cr | 1767Cr | 351Cr | 441Cr | 580Cr | 2546Cr |
| Enterprise value to EBITDA ratio | 20.62 | 12.02 | 11.80 | 4.62 | 17.60 | 8.60 | 0 | 0 | 0 | 32.10 | 15.53 | 31.60 | 29.62 | 0 | 24.10 | 22.55 | 0 | 0 | 25.59 | 0 |
| Debt to equity ratio | 2.39 | 0.40 | 0.57 | 1.14 | 1 | 1.33 | 1 | 1.57 | 2.07 | 2.34 | 2.43 | 2.79 | 3.05 | 1.85 | 3.73 | 0 | 0.04 | 0.02 | 0.02 | 0.03 |
| Return on equity % | 25.89 | 37.77 | 21.77 | -9.98 | 12.39 | 21.41 | -26.99 | -31.23 | -19.70 | -21.66 | -3.98 | -9.75 | -21.55 | 12.43 | -68.40 | 0 | 332.84 | -3.93 | -0.14 | -1 |
Panacea Biotec Ltd Ratios
The Panacea Biotec Ltd Ratios page provides a complete fundamental analysis of Panacea Biotec Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Panacea Biotec Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Panacea Biotec Ltd (NSE: PANACEABIO, BSE: 531349) is currently trading at ₹397.65, with a market capitalization of ₹2438.09Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Panacea Biotec Ltd remains a key stock for fundamental analysis using Panacea Biotec Ltd Ratios.
Panacea Biotec Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Panacea Biotec Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Panacea Biotec Ltd Ratios.
Historically, the Panacea Biotec Ltd P/E ratio has shown strong fluctuations:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0.84
- 2020: 0
The decline in Panacea Biotec Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Panacea Biotec Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.23.
Historical P/B trend:
- 2024: 3.23
- 2023: 0.88
- 2022: 0.79
- 2021: 1.04
Panacea Biotec Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Panacea Biotec Ltd P/S ratio currently stands at 5.47, an important part of Panacea Biotec Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 5.47
- 2023: 1.34
- 2022: 1.45
- 2021: 1.38
The rising Panacea Biotec Ltd P/S ratio indicates improved revenue valuation by investors.
Panacea Biotec Ltd Price to Cash Flow Ratio (P/CF)
The Panacea Biotec Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.
Historical Panacea Biotec Ltd Price to Cash Flow Ratio:
- 2024: 0
- 2023: 58.76
- 2022: 0
- 2021: 0
- 2020: 100.62
The declining Panacea Biotec Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Panacea Biotec Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Panacea Biotec Ltd EV currently stands at ₹2546Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 2546Cr
- 2023: 580Cr
- 2022: 441Cr
- 2021: 351Cr
Panacea Biotec Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Panacea Biotec Ltd EV/EBITDA ratio is currently 0, a key metric in Panacea Biotec Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 0
- 2023: 25.59
- 2022: 0
- 2021: 0
Stable Panacea Biotec Ltd EV/EBITDA indicates balanced valuation.
Panacea Biotec Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Panacea Biotec Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.03
- 2023: 0.02
- 2022: 0.02
- 2021: 0.04
Panacea Biotec Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Panacea Biotec Ltd ROE currently stands at -1%, showing profitability and capital efficiency.
Historical ROE:
- 2024: -1
- 2023: -0.14
- 2022: -3.93
- 2021: 332.84
Declining ROE indicates pressure on profitability.
Panacea Biotec Ltd Ratios Analysis Summary
The Panacea Biotec Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Panacea Biotec Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Panacea Biotec Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.